Vertex Pharmaceuticals Inc (VRTX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$425.00
Buy
$447.65
$-5.04 (-1.13%)
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
Prices updated at 31 May 2025, 00:47 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
| Year | Gross margin (%) | Operating margin (%) | Net margin (%) | EBITDA margin (%) | EBITDA |
|---|---|---|---|---|---|
| 2024 | 86.11 | 39.88 | -4.86 | 4.41 | 486m |
| 2023 | 87.21 | 43.65 | 36.68 | 46.66 | 4,605m |
| 2022 | 87.90 | 48.88 | 37.20 | 49.67 | 4,436m |
| 2021 | 88.06 | 36.69 | 30.92 | 38.52 | 2,918m |
| 2020 | 88.14 | 46.24 | 43.70 | 52.93 | 3,285m |
| 2019 | 86.84 | 28.87 | 28.27 | 37.48 | 1,560m |
| 2018 | 86.56 | 21.79 | 68.79 | 24.45 | 745m |
| 2017 | 88.95 | 15.78 | 10.58 | 4.62 | 115m |
| 2016 | 87.64 | 0.66 | -6.58 | 4.43 | 75m |
Valuation data table
| Year | Price / Sales | Price earnings | Price / Cash flow |
|---|---|---|---|
| 2025 | 10.26 | - | - |
| 2024 | 9.81 | - | - |
| 2023 | 10.97 | 30.55 | 24.18 |
| 2022 | 8.57 | 22.81 | 18.43 |
| 2021 | 8.04 | 26.33 | 26.79 |
| 2020 | 10.40 | 23.15 | 19.42 |
| 2019 | 15.73 | 26.51 | 39.60 |
| 2018 | 15.13 | 66.02 | 36.19 |
| 2017 | 16.34 | 194.62 | 49.23 |
| 2016 | 10.83 | - | 149.24 |
| 2015 | 39.83 | - | - |
Price/Forward earnings (YTD)
24.75
Returns
Debt profile
Returns data table
| Year | Return on assets (%) | Return on equity (%) | Return on invested capital (%) |
|---|---|---|---|
| 2024 | -2.37 | -3.15 | -5.38 |
| 2023 | 17.71 | 22.99 | 18.96 |
| 2022 | 21.04 | 27.67 | 25.13 |
| 2021 | 18.60 | 24.93 | 23.11 |
| 2020 | 27.02 | 36.71 | 33.52 |
| 2019 | 16.16 | 22.37 | 19.92 |
| 2018 | 42.82 | 64.87 | 55.41 |
| 2017 | 8.17 | 16.53 | 12.85 |
| 2016 | -4.15 | -10.69 | -3.36 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.37 |
| 2023 | 1.29 |
| 2022 | 1.30 |
| 2021 | 1.33 |
| 2020 | 1.35 |
| 2019 | 1.37 |
| 2018 | 1.41 |
| 2017 | 1.75 |
| 2016 | 2.50 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
